BioSpace News Archive

Considered as one of the most modern niche verticals of medical device manufacturing sector, the North America healthcare 3D printing market has gained significant prominence in recent years with the advent of innovative technologies.

Ongoing healthcare investments in the U.S. and Canada are reshaping the North America healthcare revenue cycle management market.

Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, will participate in two upcoming investor conferences

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.

Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (

BioVie Inc., a clinical-stage company developing innovative drug therapies for liver disease, announced an interview with Terren Peizer, Chairman and Chief Executive Officer, will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, February 20, at 7 p.m. local time in 73M homes across the United States.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will participate in the following virtual investor conferences

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML Bio Solutions today announced that the first patient has been dosed in a Phase 2 trial of BBP-418 in patients with LGMD2i.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, February 26, 2021 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2020